TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence
Brief Summary: This study aims to compare azathioprine versus mesalazine tablets for the prevention of clinical relapse in postoperative Crohn's disease (CD) patients with moderate or severe endoscopic recurrence.


Options:
A: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group
D: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IDE-Exempt: Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy
Brief Summary: This study will assess the impact of higher rate cutoffs and longer delays than standard programming on inappropriate therapy in primary prevention ICD and CRT-D patients.


Options:
A: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: Standard ICD programming | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: High rate cutoff | Arm Label: C; Type: EXPERIMENTAL; Interventions: Device: Long delay | Intervention Type: DEVICE; Name: Standard ICD programming; Assigned to Arm(s): A | Intervention Type: DEVICE; Name: High rate cutoff; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: Long delay; Assigned to Arm(s): C
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)
Brief Summary: The aim of the randomized double blind trial with 134 patients presenting old world cutaneous leishmaniasis is:

* to evaluate the clinical efficacy of electro-thermo-cauterisation (ETC) followed by moist wound treatment versus ETC followed by moist wound treatment plus 0.05 % pharmaceutical chlorite that has been used in three European countries (Germany, Austria and Switzerland) in wound care management for more than 20 years;
* to judge whether early wound care management would present a viable improvement to the actual anti-parasitic treatments mostly neglecting the chronic wound problem and to evaluate its long-term effect on immunity through relapse control 6 months after wound healing.


Options:
A: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device
B: Arm Label: ETC + DAC N-055; Type: EXPERIMENTAL; Interventions: Other: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: ETC + physiological saline; Type: ACTIVE_COMPARATOR; Interventions: Other: Electro-thermo-coagulation, Drug: saline | Intervention Type: OTHER; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC + DAC N-055, ETC + physiological saline | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC + DAC N-055 | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): ETC + physiological saline
C: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT
D: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)
Brief Summary: The aim of the randomized double blind trial with 134 patients presenting old world cutaneous leishmaniasis is:

* to evaluate the clinical efficacy of electro-thermo-cauterisation (ETC) followed by moist wound treatment versus ETC followed by moist wound treatment plus 0.05 % pharmaceutical chlorite that has been used in three European countries (Germany, Austria and Switzerland) in wound care management for more than 20 years;
* to judge whether early wound care management would present a viable improvement to the actual anti-parasitic treatments mostly neglecting the chronic wound problem and to evaluate its long-term effect on immunity through relapse control 6 months after wound healing.


Options:
A: Arm Label: ETC + DAC N-055; Type: EXPERIMENTAL; Interventions: Other: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: ETC + physiological saline; Type: ACTIVE_COMPARATOR; Interventions: Other: Electro-thermo-coagulation, Drug: saline | Intervention Type: OTHER; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC + DAC N-055, ETC + physiological saline | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC + DAC N-055 | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): ETC + physiological saline
B: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT
C: Intervention Type: DRUG; Name: Paromomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Brief Summary: The purpose of this study is to compare the efficacy and tolerability between clopidogrel resinate and clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD equivalents.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin Tablets | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel (over encapsulated) capsule, Drug: Aspirin Tablets | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor Tablets, Drug: Aspirin Tablets | Intervention Type: DRUG; Name: Ticagrelor Tablets; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Clopidogrel (over encapsulated) capsule; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aspirin Tablets; Assigned to Arm(s): 1, 2, 3
B: Arm Label: aspirin+placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: aspirin + placebo | Arm Label: aspirin+pregrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + pregrel (Clopidogrel resinate) | Arm Label: Aspirin+Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin + plavix (Clopidogrel bisulfate) | Intervention Type: DRUG; Name: aspirin + pregrel (Clopidogrel resinate); Assigned to Arm(s): aspirin+pregrel | Intervention Type: DRUG; Name: aspirin + placebo; Assigned to Arm(s): aspirin+placebo | Intervention Type: DRUG; Name: aspirin + plavix (Clopidogrel bisulfate); Assigned to Arm(s): Aspirin+Plavix
C: Arm Label: 75mg Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel 75 mg daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: water pill daily | Intervention Type: DRUG; Name: Clopidogrel 75 mg daily; Assigned to Arm(s): 75mg Clopidogrel | Intervention Type: DRUG; Name: water pill daily; Assigned to Arm(s): Placebo
D: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project ACTION: Adult Smoking Cessation Treatment Through Innovative Outreach to Neighborhoods
Brief Summary: This trial studies how well a mobile smoking cessation intervention works in enhancing cancer outreach in low-income adult smokers. Mobile smoking cessation intervention may help smokers quit or cut back on smoking, and help increase the range of cancer prevention services provided to low-income adult smokers.


Options:
A: Arm Label: Group I (standard care); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention | Arm Label: Group II (enhanced care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Other: Tobacco Cessation Counseling | Arm Label: Group III (intensive care); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Behavioral: Smoking Cessation Intervention, Behavioral: Telephone-Based Intervention, Other: Tobacco Cessation Counseling | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Intervention; Assigned to Arm(s): Group I (standard care), Group II (enhanced care), Group III (intensive care) | Intervention Type: BEHAVIORAL; Name: Telephone-Based Intervention; Assigned to Arm(s): Group III (intensive care) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group II (enhanced care), Group III (intensive care)
B: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral
C: Arm Label: Twitter; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation aides, Behavioral: Twitter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation aides | Intervention Type: BEHAVIORAL; Name: smoking cessation aides; Assigned to Arm(s): Control, Twitter | Intervention Type: BEHAVIORAL; Name: Twitter; Assigned to Arm(s): Twitter
D: Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Arm Label: Cell phone Aplication for Smarth Phone; Type: ACTIVE_COMPARATOR; Interventions: Device: Cell phone Aplication for Smarth Phone | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group | Intervention Type: DEVICE; Name: Cell phone Aplication for Smarth Phone; Assigned to Arm(s): Cell phone Aplication for Smarth Phone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Brief Summary: The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).


Options:
A: Arm Label: TR-701 FA; Type: EXPERIMENTAL; Interventions: Drug: TR-701 FA | Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: TR-701 FA; Assigned to Arm(s): TR-701 FA | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: oritavancin | Intervention Type: DRUG; Name: oritavancin; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: MK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A
D: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Counseling During Pulmonary Rehabilitation: Does it Improve Daily Physical Activity Levels
Brief Summary: This randomized controlled trial will assess the effect of adding intensive physical activity counseling to an outpatient pulmonary rehabilitation program. Counseling including real-time feedback on daily activities from an activity monitor will be offered to improve participation in physical activities in daily life during and after an outpatient pulmonary rehabilitation program.


Options:
A: Arm Label: KOLwebben; Type: EXPERIMENTAL; Interventions: Behavioral: KOLwebben | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: KOLwebben; Assigned to Arm(s): KOLwebben
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity counseling program | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Behavioral: sham counseling program | Intervention Type: BEHAVIORAL; Name: physical activity counseling program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: sham counseling program; Assigned to Arm(s): 2
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to tiotropium + olodaterol | Arm Label: tiotropium + olodaterol high dose with BM; Type: EXPERIMENTAL; Interventions: Drug: tiotropium +olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Arm Label: tiotropium + olodaterol with exercise training and BM; Type: EXPERIMENTAL; Interventions: Drug: tiotropium+olodaterol | Intervention Type: DRUG; Name: placebo to tiotropium + olodaterol; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium+olodaterol; Assigned to Arm(s): tiotropium + olodaterol with exercise training and BM | Intervention Type: DRUG; Name: tiotropium +olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose with BM | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Yamax Digi-Walker CW-700 | Intervention Type: DEVICE; Name: Yamax Digi-Walker CW-700; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence
Brief Summary: The goal of the proposed study is to validate an experimental paradigm to assess medication effects on smoking relapse following a brief (3-day) monitored period of smoking abstinence and a programmed cigarette lapse.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)

Answer: B